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Abstract 
Objectives: To explore patients’ interpretations of their DNA results for familial 
hypercholesterolemia (FH). 
Methods: In-depth interviews were conducted with patients from two lipid clinics in 
Scotland, who were offered genetic testing as part of a nationwide cascade screening 
service. 
Results:  Patients were receptive to taking part in genetic screening and most expected 
a positive result.  Receiving a molecular diagnosis of FH could provide reassurance to 
patients that diet and lifestyle factors were not the primary causes of their condition.  
Patients who received inconclusive results tended to interpret this as meaning that 
their high cholesterol was not genetic, which could induce feelings of uncertainty and 
self-blame.  With the exception of newly diagnosed patients, for whom a positive 
result could provide a useful rationale for initiating statins, most perceived DNA 
screening to be of little relevance to their own medication use or their own approaches 
to lifestyle management. 
Conclusions: Genetic screening for FH is highly acceptable to lipid clinic patients, 
and positive DNA results are unlikely to have deleterious psychosocial consequences.  
Patients may not, however, always interpret inconclusive DNA results correctly.  
Practice implications:  Health professionals need to ensure FH index patients are 
prepared to receive, and fully understand, inconclusive DNA results.  
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Heterozygous Familial Hypercholesterolemia (FH) is an autosomal dominant genetic 
disorder that causes elevated serum cholesterol levels and affects around one in every 
500 people
1
.  If untreated, FH leads to a greater than 50% risk of cardiovascular 
disease (CVD) in men by the age of 50 and at least 30% in women by the age of 60 
[1, 2].  The increased risk of CVD can be significantly reduced with statin therapy [3, 
4].  According to current clinical guidelines in the UK, for example, a reduction in 
low density lipoprotein cholesterol levels of 50 per cent or greater represents an 
achievable target for most FH patients, following the initiation of statin therapy
 
[1].  
However, whilst effective treatments exist and are widely available, research suggests 
that the majority of patients with FH are undiagnosed [5, 6].  One registry based study 
in the south of England, for example, found that only a quarter of the cases of FH that 
were predicted in the general population were diagnosed routinely, and most remain 
undiagnosed until middle age [5]. 
 
The under-diagnosis of FH, combined with its treatability, has made early detection 
and prophylactic intervention key priorities in preventing premature death amongst 
the population [7].  Nationwide screening initiatives for FH are already in operation in 
the Netherlands [8], Norway [9], and Spain [10]
 
and have recently been launched in 
Scotland [11] and Wales [12] in the UK, with limited service provision in England 
[13].  The use of DNA testing methods is central to these screening programmes, as 
the identification of a known mutation in index patients greatly improves the chances 
of obtaining a definitive diagnosis amongst relatives [14].  Hence, evidence suggests 
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that genetic cascade screening initiatives are cost effective [15] and may lead to 
significant reductions in mortality from CVD [16].   
 
Despite the widespread use of genetic testing in these programmes, little attention has 
been paid to how patients interpret their DNA results. One early study suggested that 
receiving a positive DNA result may increase feelings of fatalism and may result in a 
decrease in motivation to engage in risk reducing behaviours [17].  Other studies have 
indicated that genetic screening for FH is highly acceptable to patients [18] and that 
receiving a positive DNA result can result in patients becoming more aware of the 
risks of CVD [19] and  increasing their utilisation of medication [19] or viewing 
medication as more effective, and dietary control as less effective, in managing their 
condition [20].  These studies, however, are either based on qualitative interviews 
with parents, and thus explore perceptions of childhood genetic testing [17], or they 
have employed survey methods [18, 19, 20], which necessarily limit participants’ 
abilities to describe their perceptions and experiences in detail and raise issues they 
consider to be important.  Furthermore, there is a dearth of literature that explores 
how index patients interpret inconclusive results (as negative DNA test results do not 
rule out the presence of FH amongst index patients).  Given that mutation detection 
rates amongst index patients with definite/possible FH have been less than 50% in 
some European screening initiatives [21, 22], there is a need to explore how patients 
interpret inconclusive DNA results and the impact which their understandings may 
have on their perceptions of risk and their commitments towards adopting and 
maintaining self-management behaviours; for example, taking medication and 
following a healthy lifestyle. 
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Understanding how index patients interpret their genetic results is of paramount 
importance to the effective development of cascade screening initiatives, especially 
for programmes which depend on index patients coming forward and subsequently 
communicating their results correctly and effectively to family members [23, 24].  
Hence, this qualitative study aimed to explore, in-depth, interpretations of DNA 
results amongst index patients who participated in a genetic cascade screening 
initiative for FH in Scotland.  As Scotland is one of the first regions within the UK to 
develop a nationwide system of FH DNA cascade screening, which is mediated by 
patients, we were presented with a timely and important opportunity to draw upon 
their experiences in order to help inform future policy and practice decision-making. 
 
2. Methods 
2.1 The setting 
In-depth interviews were conducted with patients who participated in the FH genetic 
cascade screening service.  In Scotland, patients referred by general practices to 
specialist lipid clinics with a clinical diagnosis of possible or definite FH are normally 
asked, during their consultations, to provide blood samples for the purposes of genetic 
testing.  If a gene change is identified, patients are then referred to a genetics clinic 
[11].  At the genetics clinic, a detailed family pedigree is drawn and patients’ at-risk 
relatives are identified.  Family members are then contacted by patients using tailored 
information packs provided by staff at the genetics clinic.  If a gene mutation is not 
identified, patients receive a letter from the clinic informing them that their DNA 
results were inconclusive and recommending that family members access cholesterol 
screening.  Hence, participants with inconclusive DNA results (i.e. no gene mutation 
was identified) were not usually invited to attend clinical genetics. 
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2.2. Sampling and recruitment 
Index patients were recruited from two lipid clinics within the Lothian region of 
Scotland between May and December 2010 using an opt-in procedure.  One hundred 
and fourteen patients with DNA results, as well as the one patient who was listed as 
having formally declined genetic testing (total n=115) were identified by clinic staff 
and contacted by letter and/or face to face. Each patient received an information sheet 
outlining the study, an expression of interest form and a stamped addressed envelope.  
Patients who wished to opt-in to the study were asked to complete the expression of 
interest form and return it to the research team.  Of the 115 patients contacted, 43 
opted-in to the study.  Of these, one participant was excluded as they were below 18 
years of age; four patients were unavailable for interview.  The remaining 38 patients 
were interviewed; all of whom had undergone genetic testing and had received their 
DNA test results (Table 1). 
 
2.3 Data collection and analysis 
In order to inform the patient topic guides, NJ and NH observed 37 routine patient 
consultations, and NJ interviewed eight health professionals, at the lipid and genetics 
clinics during the study period.  The patient interviews were conducted by a non-
clinical researcher (NJ) between June and December 2010 at a time and location most 
suitable for participants.  With the exception of one interview that was conducted 
online, using instant messaging, and took over 4 hours, interviews ranged from 48 to 
116 min.  Patient topic guides included a series of open-ended questions designed to 
encourage participants to talk, at-length and in-depth, about their experiences of 
genetic testing and to raise issues that may have been unanticipated by the research 
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team.  Substantive areas included: personal and familial disease histories, perceptions 
and experiences of genetic testing; obtaining and interpreting DNA results and the 
impact of genetic testing on health behaviours.  The amount of time which had passed 
between patients receiving their DNA results and being interviewed for the study 
ranged from approximately one month to over one year. 
 
Interviews were digitally recorded, transcribed and analysed using an inductive 
thematic approach [25].  This involves concurrent data collection and analysis.  
Interview transcripts were systematically and repeatedly compared in order to identify 
cross-cutting themes and highlight common experiences.  Themes which emerged in 
early interviews were explored in-depth in subsequent interviews.  During data 
collection, transcripts were reviewed regularly and independently by NJ, NH and JL 
who met to identify common themes and discuss areas of agreement and divergence.  
A coding framework was developed to capture data relating to the primary research 
aims as well as emergent themes.  Data collection ceased at the point where no new 
themes were identified.  NVivo 8 (QSR International, Victoria, Australia), a 
qualitative data indexing package, was used to manage the data. 
 
Ethical approval for the study was obtained in January 2010 from the South East 
Scotland Ethics Committee (ref: 09/S1102/66). 
 
3. Results 
3.1 The routine nature of genetic testing 
As previously mentioned, blood samples used for DNA analysis were taken alongside 
blood samples for routine biochemical analysis.  In one of the lipid clinics, it was 
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observed that blood samples were taken prior to patients seeing the doctor and were 
sent for DNA analysis once the patient had been informed about the genetic test (and 
given consent for their blood to be used for this purpose) during their consultation 
with the doctor.  Our observations also highlighted that doctors did not discuss FH 
genetic testing at-length during these sessions but often did highlight the benefits of 
genetic testing in helping to identify affected family members. 
 
In this context, all participants described the decision to undertake genetic testing as 
straightforward and uncomplicated.  None reported that they had needed time to 
consider their decision or that they had held any substantial concerns or reservations 
prior to giving their consent.  In contrast, participants frequently described genetic 
testing for FH as involving little more than providing doctors with “a wee bit of blood 
after all” [FH20], which was “completely innocuous” [FH12].  Hence, participants 
often appeared to have “noticed no difference” [FH07] between their participation in 
genetic screening and their regular visits to the lipid clinic. As FH02 explains: 
 
“It (genetic testing) didn’t involve anything; it didn’t involve an extra visit, 
it didn’t involve an extra examination or anything like that.  It was simply a 
question of a bit more blood got taken out, but that’s no problem.” [FH02] 
 
3.2 Aiding the wider family 
The majority of participants reported that their prior dealings with health 
professionals, their experiences of following a balanced diet, and of having family 
members with high cholesterol or a family history of CVD had already led them to 
conclude that their condition was inherited. Hence, as the majority already believed 
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that a tendency towards high cholesterol ran in their family, genetic testing tended not 
to be seen, especially by more experienced lipid clinic patients, as offering any new 
insights or personal benefit. 
 
“It never really bothered me because I’ve always known, or thought, that 
there’s been a family connection anyway, you know.  So I suppose I was 
expecting the results.” [FH13] 
 
Whilst this was the case, several participants highlighted the potential benefits to 
other family members.  Children, siblings, nieces and nephews were often seen as the 
main beneficiaries of DNA results, especially when screening could help identify the 
condition in family members at an early stage and thus prevent the onset of problems 
later on in life. 
 
“I thought it (the genetic test) was a good thing because of my daughter and 
her family; that’s what I was thinking about.  She’s also a diabetic, which 
exacerbates the whole thing, so it was important to know and to advise her 
care going forward.” [FH31] 
 
Participants overwhelmingly reported positive experiences of managing their 
cholesterol levels over time and with medication, which lead them to believe 
hypercholesterolemia was an eminently manageable condition.  Hence, the potential 
to receive a positive diagnosis either for themselves or their family members did not 
appear to induce feelings of anxiety or dread amongst participants.  This, some 
participants emphasised, was in contrast to the prospect of genetic testing for other 
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conditions, such as Huntington’s disease, where effective treatment is not currently 
available.  Indeed, genetic testing for FH was only viewed as potentially anxiety 
provoking if the presence of a more serious disorder could be highlighted.  As FH18 
emphasised, “It would be much more worrying to me if somebody says, ‘Oh, by the 
way, you’ve got familial hypercholesterolemia and you’re going to have 
Alzheimer’s.’” 
 
3.3 Receiving a positive result: providing affirmation and offering reassurance 
As participants often expected genetic testing to confirm an inherited susceptibility to 
high cholesterol, receiving a positive DNA result appeared to have had little impact 
on how they viewed their condition.  As FH04 explained, “I mean, to some extent you 
just say, yeah, I knew that already.”  Only one participant gave any indication that 
receiving a positive result could have a detrimental psychological impact.  
 
“When it come back genetic I went to him (doctor), “Oh God!  That’s all I 
need!” (laughs).” [FH03] 
 
Most participants, especially those who had discovered their high cholesterol 
relatively recently, appeared to view a positive DNA result as reassuring.  This was 
because receiving a positive result allowed them to rule out, definitively, diet and 
lifestyle factors as being the primary cause of their elevated cholesterol, thus 
absolving them of any potential blame for their condition.  This did not mean, 
however, that participants who received a positive DNA result viewed diet and 
lifestyle control as being any less important following genetic testing.  In fact, some 
 11 
participants reported that receiving a positive result had helped reaffirm their 
commitment to living a healthy lifestyle. 
 
“I knew that everything I was doing I was doing for the right reasons, you 
know.  It made me grow stronger, to look after myself better.” [FH25] 
 
3.4 Surprise, uncertainty and the inconclusive DNA result 
Participants, who had received inconclusive DNA results, often reported being 
surprised by the outcome of their genetic testing as this was at odds with what they 
had expected, based on their family histories.  As FH17 explained: 
 
“I remember being surprised because I had naturally assumed it would be 
genetic, with my mother’s high cholesterol, you know, my natural assumption 
was I’m expecting this.” 
 
Of the 15 participants who received inconclusive DNA results, nine appeared - at least 
upon receiving their results letters from the lipid clinic - to have interpreted this as 
meaning that the cause of their high cholesterol was not genetic.  Participants who 
interpreted their results as negative described feeling how they may have done 
something wrong to have high cholesterol. 
 
“I suppose I thought that this test would actually prove that I had this problem 
because I had a genetic link and then it was kosher that … the NHS was taking 
me into clinics once a year and giving me all this medication, that it was ok 
because I had this genetic difficulty.  But that moment (receiving the results) 
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was the bit where, well maybe they’re doing all this for me and I’m causing 
it.” [FH16] 
 
Although the majority of participants with inconclusive DNA results reported 
encouraging family members to have their cholesterol checked, which is what they 
were advised to do by their health professionals, interpreting DNA results as negative 
could lead to the belief that other family members may not be at increased risk of 
CVD. 
 
“I know that the link isn’t there so in terms of my nieces and nephews it 
doesn’t affect them, although I’m still saying to them ‘take care’” [FH33] 
 
3.5 Starting on statins, and staying on statins    
For a minority of newly diagnosed participants, who reported undertaking genetic 
testing at the point where medication had recently been recommended, receiving a 
positive DNA result could promote receptiveness towards taking statins.  This seemed 
to be related to their belief that, while individuals had a personal responsibility to 
reduce dietary cholesterol by improving lifestyles, ‘nothing can be done’ [FH19] 
about genetic causes of high cholesterol and hence drug treatment is essential.  
Indeed, one participant specifically reported that, had she not received a positive DNA 
result, she might have been less amenable to starting on statins. 
 
“I knew that once you start statins you’re on them for the rest of your life and 
before I started them I knew that there could be some side effects so I 
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wouldn’t have gone for them unless I thought there was a good reason to do so 
and the genetic test then gave me that reason.” [FH42]   
 
In contrast, participants who reported undertaking genetic testing years after initiating 
drug treatment frequently suggested that their results had little, if any, impact on their 
behaviour.  This was because participants often viewed genetic testing and personal 
risk-management as separate spheres of activity, where the results of the former did 
not affect the latter.  As FH01, for example, stated, “I have high cholesterol for 
whatever reason and my only concern is to lower it.”  Hence, for these participants, an 
inconclusive or “negative” result was not seen as a reason for stopping or otherwise 
reducing their use of cholesterol-lowering medications, nor was a positive result seen 
as a reason for being less conscious of diet and lifestyle. 
 
“[Just] because I take a tablet doesn’t mean to say that I’m going to 
automatically eat all the wrong things because, I think, even although it’s a, 
you’ve got a genetic thing, if you’re going to be eating all the wrong things as 
well … you’re gonna make that drug work harder or you’re gonna have to 
increase your dosage or whatever.”  [FH24] 
 
4. Discussion and conclusion 
4.1 Discussion 
Participants were overwhelmingly receptive to the idea of taking part in genetic 
screening for FH.  Whilst the majority did not see any direct personal benefits to 
obtaining a molecular diagnosis, the potential for genetic testing to benefit other 
family members was often highlighted.  Positive experiences of managing high 
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cholesterol, coupled with the routine nature of the testing procedure, contributed to 
patients viewing FH genetic testing as unexceptional and non-threatening.  Based on 
their family histories and their experiences of managing their diets and lifestyles, 
participants often expected a positive result.  Receiving a positive result provided 
reassurance that diet and lifestyle were not the primary causes of participants’ 
condition, yet this did not appear to lead to participants believing that their behaviour 
was not important.  Being provided with a positive DNA result could promote 
receptiveness towards cholesterol-lowering medications amongst those new to drug 
treatment.  Participants who received inconclusive genetic results often interpreted 
this as meaning that they, and other family members, did not have a genetic 
predisposition to high cholesterol. This could lead them to question why they had high 
cholesterol, and to feel that they might have failed to manage their lifestyles 
appropriately.   
 
Studies have shown that the prospect of genetic testing for conditions where effective 
treatments and management strategies exist may induce fewer feelings of anxiety and 
concern compared with testing for less treatable conditions [26].  Our study supports 
these findings.  In line with previous qualitative research [27, 28] FH was 
overwhelmingly experienced by participants as a manageable, non-stigmatising 
condition.  Hence, participants neither reported needing time to consider their 
decision to test for a condition which they already believed they had, nor that they 
were concerned about the prospect or implications of receiving a positive result.  
Whilst experience of cholesterol as eminently manageable was a key factor promoting 
willingness to undergo genetic testing, our study also highlights that the context of 
testing is also important. A number of blood samples are routinely taken in the lipid 
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clinic.  Thus, genetic testing was, for the majority, incorporated within the taken-for-
granted flow of their clinic consultations. This may well have contributed to the 
perception of the test as ‘genetically unexceptional’ [29].  Indeed, in support of this 
suggestion, research has shown that practices in which people engage in frequently 
are often perceived as being less risky compared with those which are considered to 
be out of the ordinary [30].  Following this, patients’ perceptions of FH genetic testing 
as routine and unexceptional may have implications for how well they understand the 
testing protocol and their subsequent DNA results.  This is because, in the perception 
of routine/mundane events, patients are likely to adopt less elaborate and detailed 
considerations of the situation at hand, than might otherwise been the case when 
responding to more exceptional circumstances [30, 31]. 
 
As noted, the majority of participants who received inconclusive DNA results 
appeared to interpret this as meaning that the cause of their high cholesterol was not 
genetic.  The potential for index patients to interpret inconclusive results as meaning 
that a familial disorder is not inherited has been observed in studies of BRCA1 and 
BRCA2 mutation searching [32].  Given that mutation detection rates amongst index 
patients with possible/definite FH may be lower than 50 per cent [21, 22, 33], there is 
an obvious need to ensure that, in future, service providers are aware of the potential 
for this to happen. 
 
Findings from previous studies also suggested that FH genetic testing may influence 
risk perception and risk management behaviours [17, 19]. Our study suggests that 
prior experiences of managing hypercholesterolemia play an important role in 
determining the impact of genetic results.  For participants who reported undergoing 
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genetic testing at a point when they were deciding whether or not to initiate treatment, 
receiving a positive result could provide a useful rationale for starting statin therapy. 
This was because they overwhelmingly felt that a genetic cause of high cholesterol 
was beyond their sphere of control and, as such, medication was essential.  
Participants who were veteran patients, however, reported that the results of their 
genetic testing (be they positive or inconclusive) had little impact on their perceptions 
and behaviours.  This was because their risk perceptions and self-management 
behaviours appeared to be guided primarily by their cholesterol levels, rather than by 
disease aetiology. 
 
4.2 Study strengths and limitations 
The main strength of this study is that it provides an in-depth account of index 
patients’ experiences of genetic testing for FH, this being an important yet under-
researched area.  It is limited in that it was conducted within Scotland where the vast 
majority of participants are likely to be White British, thus restricting the extent to 
which the findings may be transferred to other countries and ethnic groups.  It must 
also be noted that approximately half of the patients interviewed were from 
professional/ skilled non-manual backgrounds (Table 1).  A similar distribution of FH 
patients’ occupational characteristics was observed in a previous qualitative study 
conducted in the UK, and was attributed to the low numbers of patients from manual 
backgrounds attending specialist lipid clinics [34].  Indeed, census research suggests 
that as little as 17% of all patients with FH may be receiving care in specialist lipid 
clinics, which are mainly located in urban areas [6].  Finally, only patients who had 
consent to genetic testing and received their DNA results were interviewed.  As such, 
we were unable to explore reasons why FH patients might decline genetic testing.  
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Future qualitative research could usefully explore interpretations of FH DNA results 
amongst patients from manual occupational backgrounds and/or from rural 
communities.  There is also scope for further qualitative research which explores 
reasons why FH patients may, or may not, attend specialist lipid clinics and why they 
may decline to participate in genetic screening. 
 
4.3 Conclusion 
Genetic testing for FH can be easily incorporated within routine lipid consultations 
and is likely to require little input in the form of specialist counselling, prior to 
patients receiving their DNA results.  Undertaking genetic testing for FH is not likely 
to result in deleterious psychosocial consequences, or to a decrease in medication use 
or lifestyle control, amongst index patients. 
 
4.4 Practice implications 
Health professionals need to be aware that index patients may interpret inconclusive 
DNA results as meaning that they and other family members do not have a genetic 
predisposition to elevated serum cholesterol levels, even if they have received a letter 
from their doctor informing them that the result is most likely due to current 
limitations in DNA screening.  Index patients should be fully informed about the 
likelihood of receiving an inconclusive result prior to undertaking genetic testing.  
Health professionals must ensure that adequate information and advice is made 
available to patients so that they fully understand their DNA results.  Health 
professionals should continue to emphasise to patients with inconclusive results that 
they and their relatives could still be at risk of developing CVD and should therefore 
undergo cholesterol screening and initiate drug treatment if appropriate. Patients 
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should also be encouraged to inform family members that they have undergone DNA 
testing and have received an uninformative result, so that family members who attend 
other clinics do not undergo DNA testing needlessly [32].  
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